191 related articles for article (PubMed ID: 19773190)
1. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
[TBL] [Abstract][Full Text] [Related]
2. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
[TBL] [Abstract][Full Text] [Related]
4. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
[TBL] [Abstract][Full Text] [Related]
5. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
[TBL] [Abstract][Full Text] [Related]
6. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
7. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
[TBL] [Abstract][Full Text] [Related]
8. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.
Bernardo L; Hermida L; Martin J; Alvarez M; Prado I; López C; Martínez R; Rodríguez-Roche R; Zulueta A; Lazo L; Rosario D; Guillén G; Guzmán MG
Arch Virol; 2008; 153(5):849-54. PubMed ID: 18299795
[TBL] [Abstract][Full Text] [Related]
9. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
[TBL] [Abstract][Full Text] [Related]
11. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus.
Lazo L; Gil L; Lopez C; Valdes I; Marcos E; Alvarez M; Blanco A; Romero Y; Falcon V; Guzmán MG; Guillén G; Hermida L
Arch Virol; 2010 Oct; 155(10):1587-95. PubMed ID: 20640909
[TBL] [Abstract][Full Text] [Related]
12. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
[TBL] [Abstract][Full Text] [Related]
13. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
[TBL] [Abstract][Full Text] [Related]
14. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
15. Domain III of the envelope protein as a dengue vaccine target.
Guzman MG; Hermida L; Bernardo L; Ramirez R; Guillén G
Expert Rev Vaccines; 2010 Feb; 9(2):137-47. PubMed ID: 20109025
[TBL] [Abstract][Full Text] [Related]
16. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus.
Izquierdo A; Bernardo L; Martin J; Santana E; Hermida L; Guillén G; Guzmán MG
Virus Res; 2008 Dec; 138(1-2):135-8. PubMed ID: 18796319
[TBL] [Abstract][Full Text] [Related]
17. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
18. A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model.
Mellado-Sánchez G; García-Machorro J; Sandoval-Montes C; Gutiérrez-Castañeda B; Rojo-Domínguez A; García-Cordero J; Santos-Argumedo L; Cedillo-Barrón L
Arch Virol; 2010 Jun; 155(6):847-56. PubMed ID: 20390312
[TBL] [Abstract][Full Text] [Related]
19. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
[TBL] [Abstract][Full Text] [Related]
20. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
